Eugen Leo
Corporate Officer/Principal at Ruprecht-Karls-Universität Heidelberg
Profile
Eugen Leo is a Professor at Ruprecht-Karls-Universität Heidelberg.
He previously worked as Vice President at Johnson & Johnson, Merck Serono SA, and Head-Clinical Development at Oxford BioTherapeutics Ltd.
From 2012 to 2018, he was the Head-Clinical Development at Isarna Therapeutics GmbH.
Dr. Leo holds an MBA degree from Colorado State University.
Eugen Leo active positions
| Companies | Position | Start |
|---|---|---|
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | - |
Former positions of Eugen Leo
| Companies | Position | End |
|---|---|---|
Isarna Therapeutics GmbH
 Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Chief Tech/Sci/R&D Officer | 2018-10-31 |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Corporate Officer/Principal | - |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Training of Eugen Leo
| Colorado State University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Private companies | 3 |
|---|---|
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Health Technology |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Eugen Leo
